DIFFERENTIATED PRODUCTS
Designing & Building
Highly
Differentiated
Products
Discover how VaultBio enhances healthcare products — achieving clinical differentiation, boosting market shares, and driving blockbuster brands.
01
TOP 20 PHARMA
Global Lifecycle Management
CHALLENGE
Two Top 20 global PharmaCos in an alliance had a 3rd-to-market product with blockbuster sales expectations. The launch strategy was underperforming, with little perceived clinical differentiation. VaultBio was engaged to develop a more competitive differentiation strategy and lifecycle plan - inclusive of phase 3 data generation, phase 4 studies, health economics, and lifecycle indications.
OUTCOME
A new focus on unique and untapped pharmacodynamic properties led to a revised brand and lifecycle strategy. The result: 90% + of clinicians surveyed indicated they would increase prescribing ~25%. The impact on within-category prescription patterns was estimated to result in a tripling of preference share.
90%+
Clinicians increasing prescribing
>$350M
Potential annual sales uplift
3x
Preference share growth
02
MIDSIZE PHARMA
New Indication
CHALLENGE
A post-launch product in the US market was performing significantly below forecast — undifferentiated clinically and significantly behind competitors on lifecycle plans. The Client had never developed a lifecycle management strategy for the product.
OUTCOME
A comprehensive lifecycle evaluation identified two new potential indications. VaultBio supported scientific and market assessment, primary research (qualitative and quantitative), forecast modeling, and executive board presentations. The client invested and successfully achieved significant expansion.
$500M+
Client investment committed
2
New indications achieved
3x
Market share increase
03
TOP 20 PHARMA
Lifecycle and 5-Year Strategy
CHALLENGE
VaultBio's client had recently launched a prescription product in a highly competitive, minimally differentiated category — in a top-five therapy class. VaultBio was engaged to build a 5-year US strategic and lifecycle plan. A significant gap in impactful clinical data led VaultBio to recommend several differentiation studies.
OUTCOME
Clinical and commercial evaluation of the global opportunity identified significant value creation pathways. Updated target product profile demonstrated increased intent to use among key customer segments, resulting in a tripling of physician preference and securing additional clinical program funding.
3x
Physician preference increase
$20M
Additional clinical program funding